Invivoscribe's subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), has secured New York State (NYS) approval for the NPM1 MRD Assay, marking an advancement to combat acute ...

NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01% ...

NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01%, ...

Review Ashdod Refinery Ltd (ARF:XTAE) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Syndax is also preparing to give new data on Revuforj at the conference, including updated results from AUGMENT-101 and the phase 1/2 SAVE trial of the drug in combination with chemotherapy and ...

From Jan 1, 2024 to Dec 31, 2024, owners who register fully electric cars and taxis will receive a rebate of 45 per cent off the Additional Registration Fee (ARF), at a revised cap of S$15,000 ...